Congress Asset Management’s C4 Therapeutics CCCC Stock Holding History
Bought
Maintained
Sold
Other funds holding CCCC
Congress Asset Management's CCCC Position: Q2 2026 in Review
Congress Asset Management increased its C4 Therapeutics (CCCC) stake by 21% in Q2 2026, buying an estimated $591K and bringing the position to 1,003,437 shares worth $4.69M. The position accounts for 0.03% of the portfolio, ranked #252.
Congress Asset Management first reported a position in CCCC in Q1 2026 and has held it in 2 quarters since. 3 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.
- Congress Asset Management held 1,003,437 shares of C4 Therapeutics worth $4.69M as of Q2 2026.
- Congress Asset Management bought 172,813 C4 Therapeutics shares in Q2 2026, an estimated $591K.
- C4 Therapeutics made up 0.03% of Congress Asset Management's portfolio in Q2 2026, its #252 holding.
- Congress Asset Management first reported a position in C4 Therapeutics in Q1 2026 and has held it in 2 quarters since.
- 3 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.
Based on Congress Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.